MARKET

INFI

INFI

Infinity Pharma
NASDAQ

Real-time Quotes | Nasdaq Last Sale

3.450
+0.020
+0.58%
Pre Market: 3.430 -0.02 -0.58% 08:58 06/14 EDT
OPEN
3.460
PREV CLOSE
3.430
HIGH
3.475
LOW
3.360
VOLUME
1.49K
TURNOVER
--
52 WEEK HIGH
5.98
52 WEEK LOW
0.7800
MARKET CAP
305.83M
P/E (TTM)
-5.3789
1D
5D
1M
3M
1Y
5Y
Shareholders May Be More Conservative With Infinity Pharmaceuticals, Inc.'s (NASDAQ:INFI) CEO Compensation For Now
Performance at Infinity Pharmaceuticals, Inc. ( NASDAQ:INFI ) has been reasonably good and CEO Adelene Perkins has done...
Simply Wall St. · 06/03 08:39
We're Not Very Worried About Infinity Pharmaceuticals' (NASDAQ:INFI) Cash Burn Rate
We can readily understand why investors are attracted to unprofitable companies. By way of example, Infinity...
Simply Wall St. · 05/28 08:17
Infinity Pharmaceuticals Files for $250 Million Mixed-Securities Shelf Offering
MT Newswires · 05/14 05:33
Infinity Pharmaceuticals (INFI) Reports Q1 Loss, Tops Revenue Estimates
Infinity (INFI) delivered earnings and revenue surprises of -7.14% and 0.86%, respectively, for the quarter ended March 2021. Do the numbers hold clues to what lies ahead for the stock?
Zacks · 05/13 22:35
BRIEF-Infinity Pharmaceuticals Reports Q1 2021 Financial Results And Provides Company Update
reuters.com · 05/13 21:34
BRIEF-Infinity Pharmaceuticals Inc Files For Mixed Shelf Of Up To $250 Million – SEC Filing
reuters.com · 05/13 21:19
Infinity Pharmaceuticals: Q1 Earnings Insights
Shares of Infinity Pharmaceuticals (NASDAQ:INFI) fell in after-market trading after the company reported Q1 results. Quarterly Results Earnings per share were up 21.05% year over year to ($0.15), which missed the estimate of ($0.12).
Benzinga · 05/13 20:40
Infinity Pharmaceuticals Q1 EPS $(0.15) Misses $(0.12) Estimate
Infinity Pharmaceuticals (NASDAQ:INFI) reported quarterly losses of $(0.15) per share which missed the analyst consensus estimate of $(0.12) by 25 percent. This is a 21.05 percent increase over losses of $(0.19) per
Benzinga · 05/13 20:27
More
Forecast
Actual (USD)
Estimate (USD)
Income StatementMore
Net Income (USD)
YoY (%)
Balance SheetMore
Total Assets (USD)
Total Liabilities (USD)
Debt to Asset (%)
Cash FlowMore
Operating (USD)
YoY (%)
Learn about the latest financial forecast of INFI. Analyze the recent business situations of Infinity Pharma through EPS, BVPS, FPS, and other data. This information may help you make smarter investment decisions.
Analyst Rating

Based on 7 analysts

Buy

Disclaimer: The analysis information is for reference only and does not constitute an investment recommendation.

Analyst Price Target
The average INFI stock price target is 8.50 with a high estimate of 12.00 and a low estimate of 4.000.
EPS
Institutional Holdings
Institutions: 102
Institutional Holdings: 42.48M
% Owned: 47.92%
Shares Outstanding: 88.65M
TypeInstitutionsShares
Increased
25
7.45M
New
38
16.74M
Decreased
9
10.51M
Sold Out
9
4.30M
  • Performance
  • Asset Allocation
  • Dividend History
No Data
Industry
Biotechnology & Medical Research
-0.29%
Pharmaceuticals & Medical Research
-0.72%
Key Executives
Chairman/Chief Executive Officer/Director
Adelene Perkins
President/Treasurer
Lawrence Bloch
Senior Vice President/Secretary
Seth Tasker
Lead Director/Independent Director
Norman Selby
Director
Samuel Agresta
Independent Director
David Beier
Independent Director
Anthony Evnin
Independent Director
Richard Gaynor
Independent Director
Michael Venuti
No Data
About INFI
Infinity Pharmaceuticals, Inc. is a biopharmaceutical company. The Company is engaged in the discovery, development and delivery of medicines to treat diseases. The Company develops small molecule drugs that target disease pathways for potential applications in oncology. Its product candidate is duvelisib, also known as IPI-145, is an oral, dual-inhibitor of the delta and gamma isoforms of phosphoinositide-3-kinase (PI3K), for the treatment of hematologic malignancies, or blood cancers. The Company is also developing IPI-549, which is an orally administered, clinical-stage, immuno-oncology product candidate that selectively inhibits the gamma isoform of PI3K. In addition to duvelisib, the Company focuses to generate new product candidates for potential investigation in oncology. The Company also focuses on developing DYNAMO, CONTEMPO, BRAVURA, FRESCO, DYNAMO+R, DUO, SYNCHRONY and Duvelisib + Venetoclax.

Webull offers kinds of Infinity Pharmaceuticals Inc. stock information, including NASDAQ:INFI real-time market quotes, financial reports, professional analyst ratings, in-depth charts, corporate actions, INFI stock news, and many more online research tools to help you make informed decisions.

You can practice and explore trading INFI stock methods without spending real money on the virtual paper trading platform.